Communiqués Cerus Corporation

Actions

CERS

US1570851014

Equipement, fournitures et distribution médicale

Temps réel estimé Cboe BZX 17:24:31 18/08/2026			Varia. 5j.	Varia. 1 janv.
2,915 ^USD	-1,85 %		+14,23 %	+42,23 %

31/07	Transcript : Cerus Corporation, Q2 2026 Earnings Call, Jul 30, 2026
30/07	Cerus Corporation révise ses prévisions de résultats pour l'exercice 2026	CI

Communiqués

30/07	Cerus: Q2 Earnings Snapshot	AQ
30/07	Cerus Corporation Announces Second Quarter 2026 Financial Results	BU
16/07	Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026	BU
17/06	Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress	BU
08/06	Cerus Corporation Closes New Debt Facility of Up to $110 Million	BU
30/04	Cerus: Q1 Earnings Snapshot	AQ
30/04	Cerus Corporation Announces First Quarter 2026 Financial Results	BU
27/04	Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System	BU
23/04	Cerus : Audit Committee Charter(Revised March 2026)	PU
16/04	Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026	BU
16/03	Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer	BU
02/03	Cerus: Q4 Earnings Snapshot	AQ
02/03	Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results	BU
23/02	Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference	AQ
20/02	Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference	BU
17/02	Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026	BU
23/01	DRK Blood Donation Service Baden-Wurttemberg, Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus INTERCEPT Blood System in Routine Clinical Practice	AQ
22/01	DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus’ INTERCEPT™ Blood System in Routine Clinical Practice	BU
11/01	Cerus : Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook	PU
11/01	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook	BU
10/12	Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America	BU
06/11	Cerus: Q3 Earnings Snapshot	AQ
06/11	Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance	BU
21/10/25	Cerus Corporation Announces Abstracts and Industry Workshop on IFC at the 2025 AABB Annual Meeting	BU
16/10/25	Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025	BU